Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-dose, Open-label, Randomized, Crossover Bioavailability Study of 200mg Tablets ZSP1273 Versus 200mg Granules ZSP1273 Under Fasted Condition in Healthy Participants

NCT06164431 is registered in ClinicalTrials.gov with Guangdong Raynovent Biotech Co., Ltd as lead sponsor.

NCT NCT06164431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06164431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-dose, Open-label, Randomized, Crossover Bioavailability Study of 200mg Tablets ZSP1273 Versus 200mg Granules ZSP1273 Under Fasted Condition in Healthy Participants
Lead sponsor
Guangdong Raynovent Biotech Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
November 23, 2023
Completion date
December 22, 2023
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalence